Instrumentalising therapeutic and enhancement drugs as pharmacological technologies with politicogenic drug effects

References

• Alexander, M. (2010). The new Jim Crow. Mass incarceration in an Age of colorblindness. The New Press.
   Google Scholar
• Askew, R., & Williams, L. (2021). Rethinking enhancement substance use: A critical discourse studies approach. The International Journal on Drug Policy, 95, 102994. https://doi.org/10.1016/j.drugpo.2020.102994
   PubMed Web of Science ®Google Scholar
• Barron, C. (Ed.). (2003). A strong distinction between humans and non-humans is no longer required for research purposes: A debate between Bruno Latour and Steve Fuller. History of the Human Sciences, 16(2), 77–99. https://doi.org/10.1177/0952695103016002004
   Web of Science ®Google Scholar
• Barry, A. (2005). Pharmaceutical matters: The invention of informed materials. Theory, Culture & Society, 22(1), 51–69. https://doi.org/10.1177/0263276405048433
   Web of Science ®Google Scholar
• Berning, M., & Hardon, A. (2016). Educated guesses and other ways to address the pharmacological uncertainty of designer drugs: An exploratory study of experimentation through an online drug forum. Contemporary Drug Problems, 43(3), 277–292. https://doi.org/10.1177/0091450916662164
   PubMedGoogle Scholar
• Bostrom, N., & Sandberg, A. (2009). Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics, 15(3), 311–341. https://doi.org/10.1007/s11948-009-9142-5
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P. (2013). Studying the effects of classic hallucinogens in the treatment of alcoholism: Rationale, methodology, and current research with psilocybin. Current Drug Abuse Reviews, 6(1), 17–29. https://doi.org/10.2174/15733998113099990002
   PubMedGoogle Scholar
• Bublitz, J.-C. (2016). Drugs, enhancements, and rights: Ten points for lawmakers to consider. In F. Jotterand & V. Dubljevic (Eds), Cognitive enhancement: Ethical and policy implications in international perspectives. Oxford University Press.
   Google Scholar
• Bullard, A. R. (2018). Neither licit nor illicit: A discursive analysis of cognition enhancers. Contemporary Drug Problems, 45(3), 262–282. https://doi.org/10.1177/0091450918789415
   Google Scholar
• Bundy, H., & Quintero, G. (2017). From mundane medicines to euphorigenic drugs: How pharmaceutical pleasures are initiated, foregrounded, and made durable. The International Journal on Drug Policy, 49, 109–116. https://doi.org/10.1016/j.drugpo.2017.08.006
   PubMed Web of Science ®Google Scholar
• Chadwick, R. (2008). Therapy, enhancement and improvement. In B. Gordijn & R. Chadwick (Eds.), Medical enhancement and posthumanity (pp. 25–38). Springer Science þ Business Media.
   Google Scholar
• Chatwin, C., Measham, F., O’Brien, K., & Sumnall, H. (2017). New drugs, new directions? Research priorities for new psychoactive substances and human enhancement drugs. The International Journal on Drug Policy, 40, 1–5. https://doi.org/10.1016/j.drugpo.2017.01.016
   PubMed Web of Science ®Google Scholar
• Clark, A., & Chalmers, D. (1998). The extended mind. Analysis, 58(1), 7–19. https://doi.org/10.1093/analys/58.1.7
   Web of Science ®Google Scholar
• Coveney, C., Gabe, J., & Williams, S. (2011). The sociology of cognitive enhancement: Medicalisation and beyond. Health Sociology Review, 20(4), 381–393. https://doi.org/10.5172/hesr.2011.20.4.381
   Web of Science ®Google Scholar
• Coveney, C., Williams, S., & Gabe, J. (2019). Enhancement imaginaries: Exploring public understandings of pharmaceutical cognitive enhancing drugs. Drugs: Education, Prevention and Policy, 26(4), 319–328. https://doi.org/10.1080/09687637.2019.1593318
   Web of Science ®Google Scholar
• Coveney, C., & Bjønness, J. (2019). Making sense of pharmaceutical cognitive enhancement: Taking stock and looking forward. Drugs: Education, Prevention and Policy, 26(4), 293–300. https://doi.org/10.1080/09687637.2019.1618025
   Web of Science ®Google Scholar
• Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., Hart, C., Kerr, T., Lajous, A. M., Lewis, S., Martin, N., Mejía, D., Camacho, A., Mathieson, D., Obot, I., … Beyrer, C. (2016). Public health and international drug policy. The Lancet Comissions, 387(10026), 1427–1480. https://doi.org/10.1016/S0140-6736(16)00619-X
   PubMed Web of Science ®Google Scholar
• Daubner, J., Arshaad, M. I., Henseler, C., Hescheler, J., Ehninger, D., Broich, K., Rawashdeh, O., Papazoglou, A., & Weiergräber, M. (2021). Pharmacological neuroenhancement: Current aspects of categorization, epidemiology, pharmacology, drug development, ethics, and future perspectives. Neural Plasticity, 2021, 8823383. https://doi.org/10.1155/2021/8823383
   PubMed Web of Science ®Google Scholar
• Daniels, N. (2000). Normal functioning and the treatment-enhancement distinction. Cambridge Quarterly of Healthcare Ethics 9(3), 309–322. https://doi.org/10.1017/s0963180100903037
   PubMed Web of Science ®Google Scholar
• Dennis, F., & Farrugia, A. (2017). Editorial. Materialising drugged pleasures: Practice, politics, care. The International Journal on Drug Policy, 49, 86–91. https://doi.org/10.1016/j.drugpo.2017.10.001
   PubMedGoogle Scholar
• Dubljevic, V. (2013). Prohibition or coffee shops: Regulation of amphetamine and methylphenidate for enhancement use by healthy adults. The American Journal of Bioethics, 13(7), 23–33. https://doi.org/10.1080/15265161.2013.794875
   PubMed Web of Science ®Google Scholar
• Duff, C. (2011). Reassembling (social) contexts: New directions for a sociology of drugs. The International Journal on Drug Policy, 22(6), 404–406. https://doi.org/10.1016/j.drugpo.2011.09.005
   PubMed Web of Science ®Google Scholar
• Duff, C. (2012). Accounting for context: Exploring the role of objects and spaces in the consumption of alcohol and other drugs. Social & Cultural Geography, 13(2), 145–159. https://doi.org/10.1080/14649365.2012.655765
   Web of Science ®Google Scholar
• Duff, C. (2015). Governing drug use otherwise: For an ethics of care. Journal of Sociology, 51(1), 81–96. https://doi.org/10.1177/1440783314562502
   Web of Science ®Google Scholar
• Duff, C. (2017). ‘Making drug realities: From analysis to praxis after the ontological turn’. Keynote at Fourth Contemporary Drug Problems Conference: ‘Making alcohol and other drug realities’. https://youtu.be/Z5YU-5K8xHc
   Google Scholar
• Dumit, J. (2012). Drugs for life. How pharmaceutical companies define our health. Duke University Press.
   Google Scholar
• Eriksen, T. H. (2016). Overheating. An anthropology of accelerated change. Pluto Press.
   Google Scholar
• Foucault, M. (1997). Technologies of the self. In Paul Rabinow (Ed.), & Robert Hurley and others (Trans.), Ethics: Subjectivity and truth by Michel Foucault. The New Press.
   Google Scholar
• Franke, A., Roser, P., Lieb, K., Vollmann, J., & Schildmann, J. (2016). Cannabis for cognitive enhancement as a new coping strategy? Results from a survey of students at four universities in Germany. Substance Use & Misuse, 51(14), 1856–1862. https://doi.org/10.1080/10826084.2016.1200619
   PubMed Web of Science ®Google Scholar
• Fraser, S., Valentine, K., & Roberts, C. (2009). Living drugs. Science as Culture, 18(2), 113–123. https://doi.org/10.1080/09505430902885441
   Web of Science ®Google Scholar
• Global Commission on Drug Policy (2017). The world drug perception problem: Countering prejudices about people who use drugs. http://www.globalcommissionondrugs.org/wp-content/uploads/2018/01/GCDPReport-2017_Perceptions-ENGLISH.pdf
   Google Scholar
• Greene, J. A., & Sismondo, S. (2015). Introduction. In S. Sismondo & J. A. Greene (Eds.), The pharmaceutical studies reader (pp. 1–16). Wiley Blackwell.
   Google Scholar
• Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(7223), 702–705. https://doi.org/10.1038/456702a
   PubMed Web of Science ®Google Scholar
• Grinspoon, L. (1994 [1971]) Marihuana reconsidered (2nd Ed., Reprint). Quick American Archives.
   Google Scholar
• Haden, M., Emerson, B., & Tupper, K. (2016). A public-health-based vision for the management and regulation of psychedelics. Journal of Psychoactive Drugs, 48(4), 243–252. https://doi.org/10.1080/02791072.2016.1202459
   PubMed Web of Science ®Google Scholar
• Hakkarainen, P., Frank, V. A., Barratt, M. J., Dahl, H. V., Decorte, T., Karjalainen, K., Lenton, S., Potter, G., & Werse, B. (2015). Growing medicine: small-scale cannabis cultivation for medical purposes in six different countries. The International Journal on Drug Policy, 26(3), 250–256. https://doi.org/10.1016/j.drugpo.2014.07.005
   PubMed Web of Science ®Google Scholar
• Hall, W., & Strang, J. (2017). Challenges in regulating the use of stimulant drugs for cognitive enhancement in normal individuals. In R. ter Meulen, A. Mohammed, & W. Hall (Eds.), Rethinking cognitive enhancement. (pp. 292–301). Oxford University Press.
   Google Scholar
• Hardon, A., & Hymans, T. D. (2016). Guest editors’ introduction: Harm reduction from below. Contemporary Drug Problems, 43(3), 191–198. https://doi.org/10.1177/0091450916663247
   PubMedGoogle Scholar
• Hardon, A., & Sanabria, E. (2017). Fluid drugs: Revisiting the anthropology of pharmaceuticals. Annual Review of Anthropology, 46(1), 117–132. https://doi.org/10.1146/annurev-anthro-102116-041539
   Google Scholar
• Hardon, A. (2021). Chemical youth. Navigating uncertainty in search of the good life. Palgrave Macmillan.
   Google Scholar
• Harris, M., & Luongo, N. (2021). “Nothing about us, without us”: Negotiating the personal and professional as activists and academics who use drugs. The International Journal on Drug Policy, 98, 103533. https://doi.org/10.1016/j.drugpo.2021.103533
   PubMedGoogle Scholar
• Hartogsohn, I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3, 205032451668317–205032451668332. https://doi.org/10.1177/2050324516683325
   Google Scholar
• Healy, D. (2004). Let them eat Prozac. In The unhealthy relationship between the pharmaceutical industry and depression. New York University Press.
   Google Scholar
• Helen, I. A. (2004). Health in prospect: High-tech medicine, life enhancement and the economy of hope. Science Studies: A Scandinavian Journal Published by the Finnish Society for Science Studies, 17(1), 3–19.
   Google Scholar
• Hofmann, B. (2017). Limits to human enhancement: Nature, disease, therapy or betterment? BMC Medical Ethics, 18(1), 56. https://doi.org/10.1186/s12910-017-0215-8
   PubMedGoogle Scholar
• Holt, M., & Treloar, C. (2008). Pleasure and drugs. International Journal of Drug Policy, 19(5), 349–352. https://doi.org/10.1016/j.drugpo.2007.12.007
   PubMed Web of Science ®Google Scholar
• Hope, V. D., Underwood, M., Mulrooney, K., Mazanov, J., van de Ven, K., & McVeigh, J. (2021). Human enhancement drugs: Emerging issues and responses. The International Journal on Drug Policy, 95, 103459. https://doi.org/10.1016/j.drugpo.2021.103459
   PubMed Web of Science ®Google Scholar
• Hupli, A., Didžiokaitė, G., & Ydema, M. (2016). Towards the smart use of smart drugs: Perceptions and experiences of university students in the Netherlands and Lithuania. Contemporary Drug Problems, 43(3), 242–257. https://doi.org/10.1177/0091450916660143
   Google Scholar
• Hupli, A. (2019). Medical cannabis for adult attention deficit hyperactivity disorder: sociological patient case report of cannabinoid therapeutics in Finland. Medical Cannabis and Cannabinoids, 1(2), 112–118. https://doi.org/10.1159/000495307
   PubMedGoogle Scholar
• Hupli, A., Didžiokaitė, G., & Ydema, M. (2019). Beyond treatment vs. enhancement: A qualitative study of pharmacological neuro-enhancement among Dutch and Lithuanian university students. Contemporary Drug Problems, 46(4), 379–399. https://doi.org/10.1177/0091450919884777
   Google Scholar
• Hupli, A. (2020). Cognitive enhancement with licit and illicit stimulants in the Netherlands and Finland: what is the evidence? Drugs and Alcohol Today, 20(1), 62–73. https://doi.org/10.1108/DAT-07-2019-002
   Web of Science ®Google Scholar
• Hupli, A. (2021). Smarter with drugs? Sociology of cognitive enhancement drugs from user’s perspectives [PhD thesis]. Faculty of Social Sciences, University of Tampere. https://trepo.tuni.fi/handle/10024/133767
   Google Scholar
• International Drug Policy Consortium (IDPC) (2018). Taking stock: A decade of drug policy — A civil society shadow report. https://idpc.net/publications/2018/10/taking-stock-a-decade-of-drug-policy-acivil-society-shadow-report
   Google Scholar
• Illich, I. (1976). Medical Nemesis. The expropriation of health. Pantheon Books.
   Google Scholar
• Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology (Oxford, England), 22(6), 603–620. https://doi.org/10.1177/0269881108093587
   PubMed Web of Science ®Google Scholar
• Jotterand, F., & Dubljević, V. (Eds.). (2016). Cognitive enhancement: Ethical and policy implications in international perspectives. Oxford University Press.
   Google Scholar
• Kegan, R. (1994). In over our heads: The mental demands of modern life. Harvard University Press.
   Google Scholar
• Klingberg, T. (2009). The overflowing brain. Information overload and the limits of working memory. Oxford University Press.
   Google Scholar
• Langlitz, N. (2010). The persistence of the subjective in neuropsychopharmacology: Observations of contemporary hallucinogen research. History of the Human Sciences, 23(1), 37–57. https://doi.org/10.1177/0952695109352413
   PubMed Web of Science ®Google Scholar
• Lancaster, K., Seear, K., & Ritter, A. (2017). Making medicine; producing pleasure: A critical examination of medicinal cannabis policy and law in Victoria, Australia. The International Journal on Drug Policy, 49, 117–125. https://doi.org/10.1016/j.drugpo.2017.07.020
   PubMed Web of Science ®Google Scholar
• Latour, B. (1994). Pragmatogonies: A mythical account of how humans and nonhumans swap properties. American Behavioral Scientist, 37(6), 791–808. https://doi.org/10.1177/0002764294037006006
   Web of Science ®Google Scholar
• Lende, D., Leonard, T., Sterk, C. E., & Elifson, K. (2007). Functional methamphetamine use: The insider’s perspective. Addiction Research & Theory, 15(5), 465–477. https://doi.org/10.1080/16066350701284552
   Web of Science ®Google Scholar
• Liokaftos, D. (2021). Sociological investigations of human enhancement drugs: The case of microdosing psychedelics. International Journal of Drug Policy, 95, 103099. https://doi.org/10.1016/j.drugpo.2020.103099
   PubMed Web of Science ®Google Scholar
• Maier, L. J., & Schaub, M. P. (2015). The use of prescription drugs and drugs of abuse for neuroenhancement in Europe: Not widespread but a reality. European Psychologist, 20(3), 155–166. https://doi.org/10.1027/1016-9040/a000228
   Web of Science ®Google Scholar
• Maier, L. J., Haug, S., & Schaub, M. P. (2015). The importance of stress, self-efficacy, and self-medication for pharmacological neuroenhancement among employees and students. Drug and Alcohol Dependence, 156, 221–227. https://doi.org/10.1016/j.drugalcdep.2015.09.012
   PubMed Web of Science ®Google Scholar
• Maier, L. J., Ferris, J., & Winstock, A. (2018). Pharmacological cognitive enhancement among non-ADHD individuals-A cross-sectional study in 15 countries. The International Journal on Drug Policy, 58, 104–112. https://doi.org/10.1016/j.drugpo.2018.05.009
   PubMed Web of Science ®Google Scholar
• Maslen, H., Faulmüller, N., & Savulescu, J. (2014). Pharmacological cognitive enhancement: How neuroscientific research could advance ethical debate. Frontiers in Systems Neuroscience, 8, 1–12. https://doi.org/10.3389/fnsys.2014.00107
   PubMedGoogle Scholar
• Medawar, C., & Hardon, A. (2004). Medicines out of control?: Antidepressants and the conspiracy of goodwill. Amsterdam.
   Google Scholar
• Moerman, D. E. (2002). Meaning, medicine and the “placebo effect.” Cambridge University Press.
   Google Scholar
• Moncrieff, J. (2009). The myth of the chemical cure. A critique of psychiatric drug treatment (Rev. Ed.). Palgrave Macmillan.
   Google Scholar
• Morrison, M. (2015). STS and enhancement technologies: A programme for future research. Science & Technology Studies, 28(2), 3–28. https://doi.org/10.23987/sts.55348
   Google Scholar
• Moyle, L., Dymock, A., Aldridge, A., & Mechen, B. (2020). Pharmacosex: Reimagining sex, drugs and enhancement. International Journal of Drug Policy, 86, 102943. https://doi.org/10.1016/j.drugpo.2020.102943
   PubMed Web of Science ®Google Scholar
• Müller, C., & Schumann, G. (2011). Drugs as instruments: A new framework for non-addictive psychoactive drug use. The Behavioral and Brain Sciences, 34(6), 231–293. https://doi.org/10.1017/S0140525X11000057
   Web of Science ®Google Scholar
• Oldani, M., Ecks, S., & Basu, S. (2014). Anthropological engagements with modern psychotropy. Culture, Medicine and Psychiatry, 38(2), 174–181. https://doi.org/10.1007/s11013-014-9374-y
   PubMed Web of Science ®Google Scholar
• Outram, S. M., & Racine, E. (2011). Examining reports and policies on cognitive enhancement: approaches, rationale, and recommendations. Accountability in Research, 18(5), 323–341. https://doi.org/10.1080/08989621.2011.606734
   PubMed Web of Science ®Google Scholar
• Petersen, M. A., Nørgaard, L. S., & Traulsen, J. (2015a). Going to the doctor with enhancement in mind: An ethnographic study of university students’ use of prescription stimulants and their moral ambivalence. Drugs, Education, Prevention and Policy, 22(3), 201–207. https://doi.org/10.3109/09687637.2014.970517
   Web of Science ®Google Scholar
• Petersen, M. A., Nørgaard, L. S., & Traulsen, J. (2015b). Pursuing pleasures of productivity: University students’ use of prescription stimulants for enhancement and the moral uncertainty of making work fun. Culture, Medicine and Psychiatry, 39(4), 665–679. https://doi.org/10.1007/s11013-015-9457-4
   PubMed Web of Science ®Google Scholar
• Petryna, A., & Kleinman, A. (2006). The pharmaceutical nexus. In A. Petryna, A. Lakoff, & A. Kleinman (Eds.), Global pharmaceuticals. Ethics, markets, practices. Duke University Press.
   Google Scholar
• Pickersgill, M. (2013). The social life of the brain: Neuroscience in society. Current Sociology. La Sociologie Contemporaine, 61(3), 322–340. https://doi.org/10.1177/0011392113476464
   PubMed Web of Science ®Google Scholar
• Pickersgill, M., & Hogle, L. (2015). Enhancement, ethics and society: Towards an empirical research agenda for the medical humanities and social sciences. Medical Humanities, 41(2), 136–142. https://doi.org/10.1136/medhum-2015-010718
   PubMed Web of Science ®Google Scholar
• Pienaar, K., Murphy, D. A., Race, K., & Lea, T. (2020). Drugs as technologies of the self: Enhancement and transformation in LGBTQ cultures. The International Journal on Drug Policy, 78(102673), 102673. https://doi.org/10.1016/j.drugpo.2020.102673
   PubMedGoogle Scholar
• Pieters, T., & Snelders, S. (2009). Psychotropic drug use: Between healing and enhancing the mind. Neuroethics, 2(2), 63–73. https://doi.org/10.1007/s12152-009-9033-0
   Web of Science ®Google Scholar
• Rogeberg, O., Bergsvik, D., Phillips, L. D., van Amsterdam, J., Eastwood, N., Henderson, G., Lynskey, M., Measham, F., Ponton, R., Rolles, S., Schlag, A. K., Taylor, P., & Nutt, D. (2018). A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. The International Journal on Drug Policy, 56, 144–152. https://doi.org/10.1016/j.drugpo.2018.01.019
   PubMed Web of Science ®Google Scholar
• Rolles, S., Schlag, A. K., Measham, F., Phillips, L., Nutt, D., Bergsvik, D., & Rogeberg, O. (2021). A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use. The International Journal on Drug Policy, 91, 103180. https://doi.org/10.1016/j.drugpo.2021.103180
   PubMed Web of Science ®Google Scholar
• Rose, N. (2003). Neurochemical selves. Society, 41(1), 46–59. https://doi.org/10.1007/BF02688204
   Web of Science ®Google Scholar
• Rose, N. (2007). The politics of life itself. In Biomedicine, power, and subjectivity in the twenty-first century. Princeton University Press.
   Google Scholar
• Rose, N. (2009). Normality and pathology in a biomedical age. The Sociological Review, 57(2_suppl), 66–83. https://doi.org/10.1111/j.1467-954X.2010.01886.x
   Google Scholar
• Schermer, M. (2007). The dynamics of treatment-enhancement distinction: ADHD as a case study. Philosophica, 79(1), 25–37. https://doi.org/10.21825/philosophica.82183
   Google Scholar
• Schermer, M., Bolt, I., de Jongh, R., & Olivier, B. (2009). The future of psychopharmacological enhancements: Expectations and policies. Neuroethics, 2(2), 75–87. https://doi.org/10.1007/s12152-009-9032-1
   Web of Science ®Google Scholar
• Science and Technology Options Assessment (STOA). (2009). Human enhancement study. http://www.europarl.europa.eu/RegData/etudes/etudes/join/2009/417483/IPOL-JOIN_ET(2009)417483_EN.pdf
   Google Scholar
• Shook, J. R., & Giordano, J. (2016). Defining contexts of neurocognitive (performance) enhancements. Neuroethical considerations and implications for policy. In F. Jotterand & V. Dubljevic (Eds.), Cognitive enhancement: Ethical and policy implications in international perspectives (p. 116). Oxford University Press.
   Google Scholar
• Silva, K., Kecojevic, A., & Lankenau, S. E. (2013). Perceived drug use functions and risk reduction practices among high-risk nonmedical users of prescription drugs. Journal of Drug Issues, 43(4), 483–496. https://doi.org/10.1177/0022042613491099
   PubMed Web of Science ®Google Scholar
• Singh, I., Filipe, A. M., Bard, I., Bergey, M., & Baker, L. (2013). Globalization and cognitive enhancement: Emerging social and ethical challenges for ADHD clinicians. Current Psychiatry Report, 15, 385. https://doi.org/10.1007/s11920-013-0385-0
   PubMed Web of Science ®Google Scholar
• Stevens, A. (2019). ‘Being human’ and the ‘moral sidestep’ in drug policy: Explaining government inaction on opioid-related deaths in the UK. Addictive Behaviors, 90, 444–450. https://doi.org/10.1016/j.addbeh.2018.08.036
   PubMed Web of Science ®Google Scholar
• Sultan, A., & Duff, C. (2021). Assembling and diversifying social contexts of recovery. The International Journal on Drug Policy, 87, 102979. https://doi.org/10.1016/j.drugpo.2020.102979
   PubMed Web of Science ®Google Scholar
• Ter Meulen, R., Mohammed, A., & Hall, W. (Eds.), (2017). Rethinking cognitive enhancement. Oxford University Press.
   Google Scholar
• Tupper, K. (2012). Psychoactive substances and the English language: “Drugs,” discourses, and public policy. Contemporary Drug Problems, 39(3), 461–492. https://doi.org/10.1177/009145091203900306
   Google Scholar
• UN (1961). Single convention on narcotic drugs. https://www.unodc.org/pdf/convention_1961_en.pdf
   Google Scholar
• van Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015). European rating of drug harms. Journal of Psychopharmacology (Oxford, England), 29(6), 655–660. https://doi.org/10.1177/0269881115581980
   PubMed Web of Science ®Google Scholar
• Van der Geest, S., Whyte, S. R., & Hardon, A. (1996). The anthropology of pharmaceuticals: A biographical approach. Annual Review of Anthropology, 25(1), 153–178. https://doi.org/10.1146/annurev.anthro.25.1.153
   Web of Science ®Google Scholar
• van de Ven, K., Mulrooney, K. J. D., & McVeigh, J. (2019). Human enhancement drugs (1st ed.). Routledge.
   Google Scholar
• Van Schipstal, I., Mishra, S., Berning, M., & Murray, H. (2016). Harm reduction from below: On sharing and caring in drug use. Contemporary Drug Problems, 43(3), 199–215. https://doi.org/10.1177/0091450916663248
   PubMedGoogle Scholar
• Varela, F., Thompson, E., & Rosch, E. (1991). The embodied mind: Cognitive science and human experience. Cambridge.
   Google Scholar
• Vitellone, N. (2003). The Syringe as a Prosthetic. Body & Society, 9(3), 37–52. https://doi.org/10.1177/1357034X030093003
   Google Scholar
• Vrecko, S. (2013). Just how cognitive is “Cognitive Enhancement”? On the significance of emotions in university students' experiences with study drugs. AJOB Neuroscience, 4(1), 4–12. https://doi.org/10.1080/21507740.2012.740141
   PubMedGoogle Scholar
• Vrecko, S. (2015). Everyday drug diversions: A qualitative study of the illicit exchange and non-medical use of prescription stimulants on a university campus. Social Science & Medicine (1982), 131, 297–304. https://doi.org/10.1016/j.socscimed.2014.10.016
   PubMed Web of Science ®Google Scholar
• Wadley, G. (2016). How psychoactive drugs shape human culture: A multi-disciplinary perspective. Brain Research Bulletin, 126(Pt 1), 138–151. https://doi.org/10.1016/j.brainresbull.2016.04.008
   PubMedGoogle Scholar
• Warso, Z. (2019). Analysis of the legal and human rights requirements for Human Enhancement Technologies in and outside the EU. SIENNA Project. https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e5c2e15872&appId=PPGMS
   Google Scholar
• Webster, A., Douglas, C., & Lewis, G. (2009). Making sense of medicines: “Lay pharmacology” and narratives of safety and efficacy. Science as Culture, 18(2), 233–247. https://doi.org/10.1080/09505430902885631
   Web of Science ®Google Scholar
• Whyte, S. R., Van der Geest, S., & Hardon, A. (2002). Social lives of medicines. Cambridge University Press.
   Google Scholar
• Williams, S., Martin, P., & Gabe, J. (2011). The pharmaceuticalisation of society? A framework for analysis. Sociology of Health & Illness, 33(5), 710–725. https://doi.org/10.1111/j.1467-9566.2011.01320.x
   PubMed Web of Science ®Google Scholar
• Wolpe, P. R. (2002). Treatment, enhancement, and the ethics of neurotherapeutics. Brain and Cognition, 50(3), 387–395. https://doi.org/10.1016/s0278-2626(02)00534-1
   PubMed Web of Science ®Google Scholar
• Zigon, J. (2015). What is a situation?: An assemblic ethnography of the drug war. Cultural Anthropology, 30(3), 501–524. https://doi.org/10.14506/ca30.3.07
   Web of Science ®Google Scholar